IL-18 Prevents the Development of Chronic Graft-Versus-Host Disease in Mice
M urine chronic graft-versus-host disease (GVHD) 2 can be induced by the transfer of DBA/2 (H-2 d ) mouse spleen cells into (C57BL/6 ϫ DBA/2)F 1 (BDF 1 ) (H-2 b/d ) mice. In this model, mice exhibit a systemic autoimmune disorder resembling human systemic lupus erythematosus (SLE), characterized by splenomegaly, host (BDF 1 ) B cell hyperactivation, autoantibody production, and immune complex deposition (1, 2) . In addition, mice with chronic GVHD exhibit increases in the number of total spleen cells, including host B cells, in the intensity of B cell MHC class II expression and in the levels of serum IgG1, IgE, and antinuclear Abs by the first week after chronic GVHD induction (3) . In this autoimmune disease model, it has been postulated that alloreactive donor (DBA/2) CD4 ϩ T cells recognize MHC class II molecules on the BDF 1 host cells, and then provide help to host B cells for autoantibody production (1, 4) . In contrast, acute GVHD caused by the injection of C57BL/6 spleen cells into BDF 1 mice is characterized by the induction of strong anti-host CTL activity, and a striking decrease in host-derived cells, resulting in weight loss and severe immunodeficiency leading to death (5, 6) .
One of the principal factors that causes the distinction between chronic and acute GVHD is considered to be the generation of donor anti-host CTL function (5, 7, 8) . Chronic GVHD mice show a 2-fold reduction in CD8
ϩ T cells and a 9-fold reduction in antihost CTL activity as compared with acute GVHD mice (4) . The defect in generating anti-host CTL activity required for the elimination of autoreactive B cells which produce pathological autoantibodies leads to a systemic disorder (9, 10) . These results suggest that moderate activation of donor CD8 ϩ T cells would result in the prevention or attenuation of chronic GVHD development without causing excessive elimination of host cells and the severe immunodeficiency observed in acute GVHD.
Because it is well known that IL-12 potentiates the cytotoxic activity of CTLs (11, 12) , experiments to treat mice with chronic GVHD with IL-12 have been performed by several laboratories (6, (13) (14) (15) . None of these attempts using IL-12, however, were satisfactory as a therapeutic approach to chronic GVHD, in that IL-12-treated chronic GVHD mice exhibited several phenotypes associated with acute GVHD, including weight loss, mortality, increased MHC class II expression, and a profound immunodeficiency as shown by a severe defect in the IL-2 production by Con A-stimulated spleen cells (13, 14) . Moreover, when IL-12 administration started after the onset of chronic GVHD, this failed to suppress autoimmune responses, including the production of anti-DNA autoantibodies (13) . Thus, IL-12 is likely to be insufficient for the treatment of chronic GVHD.
IL-18 is a recently identified and cloned cytokine, which shares some biological activities with those of IL-12 (15, 16) . IL-18 acts as a costimulatory factor for Th1 clones stimulated with Ag on APC, immobilized anti-CD3 mAb, or Con A to increase IFN-␥ production and proliferation of the Th1 clones (17, 18) . IL-18, unlike IL-12, does not drive Th1 development, but potentiates IL-12-driven Th1 development (19) . Recently, we have demonstrated that IL-18 effectively induces the development of DBA/2-derived CD8 ϩ T cells into type I effector cells in DBA/2 anti-BDF 1 MLC (20) .
In the present study, we evaluated the therapeutic and preventive effects of IL-18 administration to chronic GVHD model mice. Our results indicate that IL-18 administration at the time of chronic GVHD induction effectively prevents its onset mainly by the induction of donor anti-host CD8 ϩ CTL without any signs of acute GVHD-like symptoms. Interestingly, IL-18 treatment after the onset of clinical signs of chronic GVHD also suppressed its progression, probably by reducing an allo-specific reaction between donor CD4 ϩ T cells and host B cells.
Materials and Methods

Mice
Female DBA/2 and BDF 1 mice at 8 -10 wk of age were obtained from Japan Charles River Laboratory (Yokohama, Japan) and Japan SLC (Shizuoka, Japan). Mice were housed under standard conditions for at least 1 wk before our experiments.
Induction of chronic GVHD
DBA/2 mouse spleen cells (9 ϫ 10 7 viable cells) were transferred by i.v. injection into BDF 1 mice as described previously (12) . Normal BDF 1 mice were injected with FCS-free RPMI 1640 medium as controls.
IL-18 treatment
Murine rIL-18 was generated by expression of IL-18 cDNA in Escherichia coli and was purified by several steps of column chromatography, as described previously (20) . The endotoxin content was Ͻ1 ng/mg, as measured by the Limulus amebocyte lysate assay. Experimental mice received IL-18 i.p. at 0.1, 1, and 10 g/0.1 ml PBS containing 0.1% mouse serum albumin on days 0 -5 or days 8 -13 after the induction of chronic GVHD. Control chronic GVHD mice received PBS containing 0.1% mouse serum albumin.
IL-12 treatment
Murine rIL-12 was expressed in Chinese hamster ovary (CHO) cells and was purified from the supernatants of the CHO cell cultures by several steps of column chromatography, as described previously (20) . The specific activity was 5.5 ϫ 10 6 U/mg. The endotoxin content was Ͻ30 ng/mg. IL-12 was injected i.p. into chronic GVHD mice at 0.1 g/0.1 ml PBS containing 0.1% mouse serum albumin on days 8 -13 after the induction of chronic GVHD.
Flow cytometry
Spleen cells from GVHD mice and normal mice were analyzed for the percentages of donor CD8
, and host B cells (H-2K bϩ , CD19 ϩ ) using anti-CD4 mAb (GK1.5), anti-CD8 mAb (53-6.7), or anti-CD19 mAb (1D3) followed by FITC-conjugated F (abЈ) 2 fragments of goat anti-rat IgG and PE-conjugated anti-H-2K b mAb (AF6-88.5), all of which were obtained from PharMingen (San Diego, CA). Isotype-matched control Abs were used for background staining. Spleen cells were also assessed for the intensity of host B cell MHC class II expression using PE-conjugated anti-I-A b mAb (AF6-120.1; PharMingen). Cells were washed three times in PBS supplemented with 1% FCS and 0.05% sodium azide after incubation with each mAb on ice for 30 min. After viable lymphocytes had been gated by forward and side scatter, stained cells were analyzed on an EPICS Profile II flow cytometer (Coulter Electronics, Hialeah, FL).
Induction and measurement of cytokine production in vitro
Spleen cells (5 ϫ 10 6 /well) from experimental mice were cultured in 24-well plates with 5 g/ml Con A in RPMI 1640 medium containing 10% FCS, 5 ϫ 10 Ϫ5 M 2-ME (Life Technologies, Grand Island, NY), 60 g/ml penicillin, and 50 g/ml streptomycin. Cells were cultured for 24 h or 48 h at 37°C to assess the levels of IL-2 and IFN-␥ production, respectively. The cell-free supernatants were collected and frozen at Ϫ20°C until being assayed. Sandwich ELISAs were used to determine IL-2 and IFN-␥ levels. The mAbs for plate coating and biotinylated secondary mAb were as follows: for IL-2, rat anti-mouse IL-2 mAb (JES6-1A12; PharMingen) and biotinylated rat anti-mouse IL-2 mAb (JES6-5H4; PharMingen); for IFN-␥, rabbit anti-mouse IFN-␥ polyclonal Ab prepared in our laboratory and biotinylated rat anti-mouse IFN-␥ mAb (XMG1.2; PharMingen).
Measurement of serum Igs
Sera were collected from individual mice and serum levels of IgG1 and IgE were determined by sandwich ELISA. Briefly, purified rat anti-mouse IgG1 mAb (A85-3; PharMingen) and HRP-conjugated rat anti-mouse IgG1 (Zymed, San Francisco, CA) for IgG1, or rat anti-mouse IgE mAb (6HD5, Yamasa, Chiba, Japan) and biotinylated rat anti-mouse IgE mAb (HMK-12, Yamasa) for IgE, were used for plate coating and secondary Abs for ELISA. Mouse IgG1 (S1-68.1; PharMingen) and mouse IgE (IgE-3; PharMingen) were used as standards in these assays.
Serum titers of IgG antinuclear Abs were also assessed by ELISA as described previously (21) . Briefly, microtiter plates were coated with calf thymus DNA (Sigma, St. Louis, MO) at 5 g/ml in PBS, and were incubated with serially diluted serum. Plates were then developed by the addition of biotinylated rat anti-mouse IgG (Vector Laboratories, Burlingame, CA) followed by the addition of HRP-labeled streptavidin (Zymed). Cr-labeled target cells in 96-well round-bottomed plates for 4 h at 37°C. The percentage of specific lysis was calculated according to the following formula: percent specific lysis ϭ [(cpm experimental Ϫ cpm spontaneous)/(cpm maximum Ϫ cpm spontaneous)] ϫ 100.
Cr release assay to test cytotoxic activity
Statistical analysis
All statistical analyses were performed using Student's t test. The p values Ͻ0.05 were considered statistically significant.
Results
Early IL-18 treatment prevents the development of chronic GVHD without causing acute GVHD
To determine whether IL-18 administration inhibits the development of chronic GVHD, chronic GVHD was induced by injecting DBA/2 spleen cells into BDF 1 mice. IL-18 was administered in three doses (0.1, 1, and 10 g/day) on days 0-5 after the induction of chronic GVHD. On day 16 after the induction, control PBS-treated mice exhibited the following findings typical of chronic GVHD, as previously described (3, 13): splenomegaly; an increase on host B cells; elevated serum Ab levels of IgG1, IgE, and IgG antinuclear Abs; and an increase in the level of MHC class II (I-A b ) expression on host B cells, a sign of host B cell activation, as compared with those of normal BDF 1 mice ( Fig. 1 and Table I ). Although host macrophages also expressed the I-A b molecule, their percentages in the spleen cells were Ͻ3% in all experiments and were not affected by the IL-18 administration (data not shown). The expression intensity of the I-A b molecule was therefore regarded as reflecting the activation levels of host splenic B cells and is used as an activation marker of host B cells in the literature (3, 13) . In addition to the features of chronic GVHD described above, the IL-2 and IFN-␥ productions by Con A-stimulated spleen cells from control chronic GVHD mice were reduced to 20% and 12% of those produced by spleen cells from normal BDF 1 mice, respectively (Table II) .
Normal BDF 1 mice that received 10 g/day of IL-18 exhibited a 1.1-to 1.2-fold increase in the number of spleen cells compared with those in PBS-treated BDF 1 mice (Table I) , and a minimal increase in serum Igs levels ( Fig. 1 ), although these changes were not significant. However, as evaluated by flow cytometric analysis shown in Table I , these IL-18-treated BDF 1 mice did not show any significant changes in the percentages and in the number of CD4 ϩ and CD8 ϩ T cells, or of B cells in the spleen when compared with PBS-treated BDF 1 mice. Thus, it is unlikely that IL-18 administration into normal BDF 1 mice seriously affects their immunological phenotypes.
IL-18 treatment for 6 days starting on the day of chronic GVHD induction inhibited the serum titers of IgG1, IgE, and IgG antinuclear Abs in a dose-dependent manner ( Fig. 1) (1 g/day, p Ͻ 0.05; 10 g/day, p Ͻ 0.01 vs PBS control group), although the lowest dose of IL-18 (0.1 g/day) had a minimal effect that was not statistically significant ( Fig. 1 ). IL-18 treatment (10 g/day) almost completely suppressed the elevation of these serum Abs to levels equal to those observed in normal BDF 1 mice. In parallel with these results, the IL-18 treatment significantly decreased the number of host B cells, and the mean fluorescence intensity of the MHC class II expression on host B cells (1 g/day, p Ͻ 0.05; 10 g/day, p Ͻ 0.005 vs PBS control group) ( Table I) . In another report, the appearance of the acute GVHD phenotype was defined as a Ͼ50% reduction in host-derived cells in the spleen (7). However, none of the IL-18-treated mice displayed a severe decrease in the ratio of host cells to donor cells (the percentages of host cells was 79.6 Ϯ 11.4% of all spleen cells in mice receiving 10 g/day of IL-18). Additionally, neither weight loss nor mortality was observed in any of the mice in the IL-18-treated groups during the 16 days (changes in body weight were within 10% of the starting weight; data not shown), and all five mice treated with IL-18 were still alive at 100 days (data not shown). Importantly, IL-18 treatment dose-dependently partially restored both IL-2 and IFN-␥ production from spleen cells upon stimulation with Con A (Table II) ( p Ͻ 0.05). This IL-18-induced restoration of IL-2 and IFN-␥ does not seem to be caused by a nonspecific immunomodulatory effect of IL-18, because the augmentation of both IL-2 and IFN-␥ production was not observed with spleen cells from normal BDF 1 FIGURE 1. IL-18 treatment inhibits the increase in serum IgG antinuclear Abs, IgG1, and IgE levels in chronic GVHD mice. Chronic GVHD was induced on day 0. IL-18 treatment was initiated at the time of chronic GVHD induction. On day 16 after chronic GVHD induction, sera were obtained from normal BDF 1 306 Ϯ 113* 8.5 Ϯ 6.1* a Chronic GVHD was induced on day 0 as described in Materials and Methods. On day 16 after chronic GVHD induction, spleen cells (5 ϫ 10 6 /well) from mice receiving 0.1, 1 or 10 g of IL-18, or PBS on days 0 -5 were cultured in the presence of 5 g/ml Con A. Spleen cells from normal BDF 1 mice receiving PBS or 10 g of IL-18 on days 0 -5 were also stimulated with Con A. Culture supernatants were collected after 24 and 48 h for assessing IL-2 and IFN-␥ levels by ELISA, respectively. Assays were performed in triplicate per mouse and the results are expressed as the mean Ϯ SD of five mice per group.
‫,ء‬ p Ͻ 0.05 compared with the chronic GVHD control group treated with PBS.
mice injected with IL-18 on days 0 -5 (Table II) . Furthermore, these findings contrasted with the effect of IL-12 treatment as shown by Via et al. (13) . They reported that IL-12 treatment (0.1 g/day) for 5 days starting on the day of chronic GVHD induction further compromised the IL-2 production by Con A-stimulated spleen cells compared with that of control chronic GVHD mice, indicating the development of an acute GVHD phenotype. Taken together, these results suggest that the administration of IL-18 effectively prevents the onset of chronic GVHD without any features of acute GVHD.
IL-18 treatment of chronic GVHD mice changes the balance of donor CD4 ϩ and CD8 ϩ T cell numbers, and selectively decreases host B cells
Interestingly, 1 g/day of IL-18 treatment for 6 days, starting on the day of cell transfer, decreased the number of host B cells by 54% compared with those in the PBS control group, although this decrease corresponds to only an 8% reduction in total spleen cells (Table I) . On the other hand, 10 g/day of IL-18 treatment resulted in a further 17% reduction in the number of host B cells and a 54% reduction in the number of total spleen cells as compared with those in the 1 g/day of the IL-18 treatment group. These results suggest that in the chronic GVHD mice treated with IL-18, host B cells are first eliminated, followed by the elimination of other hostderived cells, including host T cells depending on the dose of IL-18. To ascertain this possibility, we examined the effect of IL-18 treatment (1 g/day) on donor and host T cell numbers. As shown in Table III, donor CD4 ϩ T cells were reduced by 46% in the spleens of IL-18-treated mice, whereas the number of donor CD8 ϩ T cells increased 1.8-fold compared with those in PBStreated chronic GVHD mice. On the other hand, as we expected, little or no change in the number of both CD4 ϩ and CD8 ϩ host T cells was observed in IL-18-treated mice, whereas the number of host B cells was reduced to 25%. In contrast, in the case of 10 g/day of IL-18 treatment, both CD4
ϩ and CD8 ϩ host T cells were also significantly reduced in number (data not shown). These results suggest that host B cells were selectively eliminated in the case of administration with 1 g/day of IL-18 in DBA/2 cellinjected BDF 1 mice. These results further suggest that IL-18 may activate donor CD8
ϩ T cells and induce the development of CD8 ϩ CTL, resulting in the elimination of activated host B cells.
IL-18 treatment ameliorates the immunological findings of chronic GVHD when initiated even after the onset of clinical signs
It was reported that delayed IL-12 treatment (days 8 -12) of chronic GVHD mice cannot decrease the serum anti-DNA Ab levels and host B cell numbers (13) . To address the question of whether IL-18 treatment can suppress ongoing chronic GVHD, we started the administration of IL-18 (1 or 10 g/day) to chronic GVHD mice 8 days after induction. In kinetic studies, on day 8, DBA/2 cell-injected BDF 1 mice developed clinical signs of chronic GVHD characterized by splenomegaly (1.2-fold increase in the total number of spleen cells), together with an elevated serum IgG antinuclear Abs, IgG1, and IgE ( p Ͻ 0.05 vs normal BDF 1 mice) (data not shown). During the administration of IL-18 (days 8 -13), neither weight loss nor death was observed (data not shown). All mice were studied 16 days after cell transfer. In the IL-18-treated groups, the total number of spleen cells tended to decrease, although there were no statistically significant differences (Table IV) . Host B cell numbers and their MHC class II expression intensity were significantly decreased in the IL-18-treated group by 28% and 23%, respectively, compared with the PBS control group (10 g/day, p Ͻ 0.05) (Table IV) . Donor CD4 ϩ T cells decreased in number after delayed treatment with IL-18 (10 g/day) (69% reduction, p Ͻ 0.05 vs PBS control group), although unlike in early IL-18 treatment (days 0 -5), donor CD8 ϩ T cells in the spleen did not increase. As shown already in Tables I and III , similar results were also obtained when IL-18 (1 g/day) was administered on days 0 -5 after the chronic GVHD induction (MHC class II expression, 39% reduction; donor CD4 ϩ T cell number, 46% reduction). Thus, regardless of the timing of the treatment, IL-18 significantly decreased the number of donor CD4 ϩ T cells and the level of host B cell MHC class II expression.
As shown in Fig. 2 , delayed IL-18 treatment (days 8 -13) significantly suppressed the serum IgG antinuclear Ab levels as compared with those in the PBS control group ( p Ͻ 0.05). The IL-18 treatment also significantly decreased the serum IgG1 levels (1 and 10 g/day) and the IgE levels (10 g/day) compared with those in the PBS control group ( p Ͻ 0.05). To compare the effect of IL-18 treatment on the serum IgG antinuclear Ab levels with that of IL-12 treatment, chronic GVHD mice were administered 0.1 g/ day of IL-12 according to the same schedule as that for IL-18 treatment (days 8 -13). We confirmed that the delayed administration of IL-12 failed to decrease serum IgG antinuclear Ab levels, although it suppressed serum IgG1 and IgE levels, as previously reported (Fig. 3 and data not shown) (13) . Moreover, we observed that chronic GVHD mice injected with IL-12 (0.1 g/day) exhibited 1.7-fold greater splenomegaly (3.1 Ϯ 0.5 ϫ 10 8 cells vs 5.3 Ϯ 1.1 ϫ 10 8 cells, p Ͻ 0.05) and tended to have increased host B cell numbers compared with those in the PBS control group (no significant difference; data not shown). We next assessed whether delayed IL-18 treatment will also restore the impaired IL-2 and IFN-␥ production upon stimulation of the spleen cells with Con A. As shown in Table V , both IL-2 and IFN-␥ production in the culture supernatants were significantly increased in the IL-18-treated group (10 g/day groups, p Ͻ 0.05). No clear IL-18 dose response in these data may suggest that the effect of IL-18 at a dose ranging from 1 to 10 g/day has reached a plateau level. Taken together, our results indicate that even after the onset of chronic GVHD, IL-18 treatment significantly ameliorates the progression of chronic GVHD.
Anti-host CTL activity of donor CD8 ϩ T cells increases in chronic GVHD mice treated with IL-18
In the preceding sections, we showed that increased donor CD8 ϩ T cells and decreased host B cells were observed in IL-18-treated chronic GVHD mice when compared with control PBS-treated mice, especially when treatment started immediately after the chronic GVHD induction. In addition, our previous in vitro study demonstrated that IL-18 induces the development of DBA/2-derived naive CD8 ϩ T cells into type I effector cells in DBA/2 anti-BDF 1 MLC (20) . Therefore, we investigated whether the in vivo preventive effect of IL-18 on the development of chronic GVHD was due to the elimination of host B cells by IL-18-induced CD8 ϩ CTL. To examine the anti-host CTL activity in chronic GVHD mice treated with IL-18 (1 g/day, days 0 -5), spleen cells harvested 10 days after induction were stimulated with mitomycin 370 Ϯ 65* 4.1 Ϯ 3.7 GVHD ϩ 10 g IL-18
325 Ϯ 58* 2.7 Ϯ 0.8* a Chronic GVHD mice received injections of 1 or 10 g of IL-18, or PBS on days 8 -13 (n ϭ 5/group). On day 16, spleen cells (5 ϫ 10 6 /well) from the mice were cultured with 5 g/ml Con A. Culture supernatants were collected at 24 and 48 h for IL-2 and IFN-␥ production, respectively. IL-2 and IFN-␥ levels were determined by ELISA. Assays were performed in triplicate per mouse, and the results are expressed as the mean Ϯ SD of five mice per group.
‫,ء‬ p Ͻ 0.05 compared with the PBS control group.
C-treated BDF 1 spleen cells for 5 days, and then the cytotoxic function of the cultured cells was analyzed using 51 Cr-labeled EL-4 (H-2 b ) and P815 (H-2 d ) as target cells. No lysis against donor-type P815 was observed in any group (Ͻ1% specific lysis). The spleen cells from IL-18-treated chronic GVHD mice showed CTL activity specific for host-type EL-4 cells (15% at E:T ratio of 50:1, Fig. 4) , whereas a minimal CTL response was detected in the PBS control group (3.3% at E:T ratio of 50:1), as reported previously in similar experiments (4). This result indicates that IL-18 treatment is able to elicit donor anti-host CTL activity, suggesting that the IL-18-induced donor anti-host CTL then eliminates activated host B cells.
Because IL-18 could induce specific anti-host CTL responses in vivo, we further examined whether this anti-host cytotoxic activity was ascribed to donor CD8 ϩ CTL. As shown in Fig. 4 , depletion of CD8 ϩ T cells from the effector cells using anti-CD8 mAb completely abrogated the IL-18-induced CTL activity (1.5% at E:T ratio of 50:1). These data show that the administration of IL-18 into DBA/2 cell-injected BDF 1 mice induces anti-host CD8 ϩ CTL. These results further suggest that the activation of donor CD8 ϩ T cells is important in the prevention of chronic GVHD development.
We next examined the effect of IL-18 treatment after the onset of immunological evidences of chronic GVHD on the induction of donor anti-host CTL. However, we could not detect any cytotoxic activity against EL-4 cells in the spleen cells from chronic GVHD mice that received IL-18 (1 or 10 g/day) on days 8 -13 (Ͻ3% at an E:T ratio of 100:1 in two separate experiments). This result correlated with the observation that we could not see an increase in the number of donor CD8 ϩ T cells after delayed IL-18 treatment (Table V) . These results suggest that delayed IL-18 treatment reduces the number of host B cells by a mechanism other than the development of donor anti-host CTL.
Discussion
A central issue in therapeutic strategies for chronic GVHD in mice is that treatment using cytokines such as IL-12 often leads conversion of the chronic GVHD into acute GVHD-associated immunodeficiency and mortality (6, 13, 14) . Although early IL-12 treatment (days 0 -4) could generate anti-host CTL required for the elimination of host autoantibody-producing B cells, it was difficult to administer any dose of IL-12 that prevented the development of chronic GVHD without inducing an acute condition (13) . The data presented here demonstrate that IL-18 treatment simultaneous with DBA/2 cell transfer prevents the development of chronic GVHD without any clinical signs of acute GVHD. These results suggest that the administration of IL-12 or IL-18 to DBA/2 cell-injected BDF 1 mice apparently display different effects, although IL-18 is known to share several biological functions with IL-12. These results further suggest that the use of IL-18 rather than IL-12 may have the potential to overcome chronic GVHD.
No conversion into acute GVHD after IL-18 treatment may be ascribed to the reduction in the number of donor CD4 ϩ T cells. Our present results show that DBA/2 cell-injected BDF 1 mice treated with IL-18 exhibited reduced numbers of donor CD4
ϩ T cells regardless of the timing of the administration. These results were in accordance with our previous in vitro study that CD4 ϩ T cells decreased in DBA/2 anti-BDF 1 MLC in the presence of IL-18, whereas CD8 ϩ T cells increased (20) . Recently, Buhlmann et al. (22) demonstrated that donor CD4 ϩ T cells that produce IL-2 and express CD40 ligand are required not only for the induction, but also for the sustained expansion of donor effector CD8 ϩ T cells in C57BL/6 cell-injected BDF 1 mice with acute GVHD. In addition, donor CD4 ϩ T cells seem to play a pivotal role in causing lethal acute GVHD (23) . These findings suggest that the decrease in donor CD4 ϩ T cells in DBA/2 cell-injected BDF 1 mice treated with IL-18 may play a role as a negative feedback mechanism in the sustained expansion of donor CD8 ϩ CTL, resulting in the prevention of conversion to acute GVHD.
Another possibility for the mechanism of preventing conversion into an acute phenotype in IL-18-treated mice could be also considered. IFN-␥ induced by IL-18 administration to chronic GVHD mice may play a role in blocking the conversion to acute GVHD. It has been postulated that IFN-␥ production would lead to exacerbation of acute GVHD (24 -26) . However, IFN-␥ knock-out mice used as donors in a mouse acute GVHD model accelerated acute GVHD-associated morbidity (27) . Similarly, a recent study demonstrated that the protection of acute GVHD by IL-12 treatment was dependent on donor-derived IFN-␥ production (28) . We could observe high levels of IFN-␥ in the serum of chronic GVHD mice treated with 10 g/day of IL-18 on days 0 -5 (sera were obtained from a pool of three mice) (Ͻ0.5, 44.9, 70.5, and 1.9 IU/ml on days 2, 4, 5, and 7, respectively), whereas IFN-␥ in the serum from control PBS-treated chronic GVHD mice was undetected. Therefore, it is probable that IFN-␥ serves to protect from conversion into the acute phenotype in IL-18-treated chronic GVHD mice.
Our present study is the first demonstration that IL-18 treatment even after the onset of clinical symptoms (days 8 -13) ameliorates the immunological findings associated with chronic GVHD. However, this efficacy of the delayed IL-18 treatment was attenuated compared with that of early IL-18 treatment during the first week (days 0 -5). The attenuated effect on chronic GVHD was similarly observed in delayed treatment with IL-12 (13) . It has been reported that the progression of chronic GVHD during the first 2 wk is associated with skewing donor T cells toward a Th2 phenotype (3, 29, 30) . Therefore, the diminished effect of delayed treatment may be, in part, accounted for by a decrease in the responsiveness of T cells to IL-18 or IL-12 in chronic GVHD mice during the first 2 wk, because expression of the IL-18 receptor is known to be downregulated in Th2 cells (31, 32) . In fact, IFN-␥ production by spleen cells from chronic GVHD mice (n ϭ 3) on day 8 in response to 10 ng/ml of IL-18 was reduced to about one-third of that produced by spleen cells on day 2 (day 2,378 Ϯ 45 IU/ml; day 8, 132 Ϯ 15 IU/ml).
The preventive and therapeutic effects of IL-18 on chronic GVHD may be explained by two additional findings, besides the induction of donor anti-host CD8 ϩ CTL as important effector cells for eliminating host B cells. First, chronic GVHD mice treated with IL-18 suppressed the level of MHC class II (I-A b ) expression, thus leading to a reduction in Ag presentation to donor CD4 ϩ T cells. In contrast, IL-12 treatment up-regulated this expression, as shown by Via et al. (13) . Recently, it has been reported that IFN-␥ down-regulates MHC class II expression on B cells, whereas it up-regulates its expression on macrophages (33). Furthermore, as described above, we could detect significant amounts of IFN-␥ in the serum of chronic GVHD mice treated with IL-18 on days 0 -5. Thus, IFN-␥ induced by IL-18 may suppress host B cell MHC class II expression. However, we could detect little IFN-␥ production in the sera of chronic GVHD mice after delayed treatment with IL-18 (data not shown), whereas we could observe downregulation of MHC class II expression on B cells by this treatment. Thus, because we were not able to thoroughly rule out the possibility that IFN-␥ induced by IL-18 treatment suppressed MHC class II expression, another mechanism may also be responsible for the IL-18-mediated suppression of MHC class II expression. Second, IL-18 administration suppressed the engraftment of donor CD4 ϩ T cells by as yet unknown mechanisms. A recent study suggests that the onset of chronic GVHD is caused by the immune response of donor CD4 ϩ T cells which recognize host alloantigen on host APC, and then the donor CD4 ϩ T cells help host B cells to produce autoantibody (1, 4) . Moreover, Via et al. (34) have shown that blockade of CD28/CTLA-4: B7 interaction by CTLA4-Ig in ongoing chronic GVHD mice prevents the development of Th2-deriven responses, along with down-regulation of B cell MHC class II expression and reduced numbers of donor CD4 ϩ T cells. In their studies, they also postulated that systemic autoimmune disease, such as chronic GVHD, requires continuous CD4 ϩ T cell help for B cells. Thus, it is possible that the decrease in donor CD4 ϩ T cell numbers and in host B cell MHC class II expression resulted in the suppression of alloantigen-specific immune responses, such as Ab production by host B cells. Therefore, a reduced interaction between donor CD4 ϩ T cells and host B cells by altering the surface expression of MHC class II or costimulatory molecules may be a beneficial approach for the treatment of chronic GVHD in mice.
It is well recognized that human SLE patients manifest immunological features such as autoreactive B cell activation and autoantibodies production that are similar to those observed in the chronic GVHD mice used in the present study (1, 4, 10) . Furthermore, it has been shown that both in human SLE and in chronic GVHD mice, CD4
ϩ T cell-B cell interaction is required for producing autoantibodies by B cells (10, 34, 35) . These results together with the findings obtained from our present study suggest that IL-18 may have beneficial effects on the treatment of human SLE.
It has been shown that Th1-mediated immune responses are dominated in acute GVHD mice (3, 5) . In addition, anti-host CTL effectors play an important role in mediating acute GVHD (5, 7). Furthermore, we have shown that Th1 response-related cytokine IL-18 induces CD8 ϩ CTL development in in vitro (20) and the present in vivo study. These results suggest that in acute GVHD model mice IL-18 may be involved in its pathogenesis through the induction of CTL development. To clarify this possibility, further studies with acute GVHD mice need to be performed.
In summary, the effects of IL-18 on the development of chronic GVHD may be ascribed to the following IL-18-mediated triple action; the induction of donor anti-host CD8 ϩ CTL, the downregulation of host B cell MHC class II expression, and the decrease in donor CD4 ϩ T cell numbers. To ascertain the mechanism for these IL-18-mediated effects, further experiments are necessary. Our findings presented in this study would provide new strategies using IL-18 for the treatment of chronic GVHD in mice and human autoimmune diseases, such as SLE.
